
Stemtech Corporation
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $0.0385
- Today's High:
- $0.0418
- Open Price:
- $0.0418
- 52W Low:
- $0.0311
- 52W High:
- $1.7
- Prev. Close:
- $0.0418
- Volume:
- 74628
Company Statistics
- Market Cap.:
- $3.88 million
- Book Value:
- -0.006
- Revenue TTM:
- $4.39 million
- Operating Margin TTM:
- -137.49%
- Gross Profit TTM:
- $3.30 million
- Profit Margin:
- 327.57%
- Return on Assets TTM:
- -82.68%
- Return on Equity TTM:
- 0%
Company Profile
Stemtech Corporation had its IPO on under the ticker symbol STEK.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Stemtech Corporation has a staff strength of 0 employees.
Stock update
Shares of Stemtech Corporation opened at $0.04 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.04 - $0.04, and closed at $0.04.
This is a -4.31% slip from the previous day's closing price.
A total volume of 74,628 shares were traded at the close of the day’s session.
In the last one week, shares of Stemtech Corporation have increased by +2.56%.
Stemtech Corporation's Key Ratios
Stemtech Corporation has a market cap of $3.88 million, indicating a price to book ratio of 0 and a price to sales ratio of 1.5362.
In the last 12-months Stemtech Corporation’s revenue was $4.39 million with a gross profit of $3.30 million and an EBITDA of $-4071567. The EBITDA ratio measures Stemtech Corporation's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Stemtech Corporation’s operating margin was -137.49% while its return on assets stood at -82.68% with a return of equity of 0%.
In Q2, Stemtech Corporation’s quarterly earnings growth was a positive 0% while revenue growth was a negative 11.6%.
Stemtech Corporation’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0.1174
- PEG
Its diluted EPS in the last 12-months stands at $0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Stemtech Corporation’s profitability.
Stemtech Corporation stock is trading at a EV to sales ratio of 1.8342 and a EV to EBITDA ratio of -1.8408. Its price to sales ratio in the trailing 12-months stood at 1.5362.
Stemtech Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $4.40 million
- Total Liabilities
- $5.71 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Stemtech Corporation ended 2025 with $4.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $4.40 million while shareholder equity stood at $-568037.00.
Stemtech Corporation ended 2025 with $0 in deferred long-term liabilities, $5.71 million in other current liabilities, in common stock, $-24154890.00 in retained earnings and $467409.00 in goodwill. Its cash balance stood at $283878.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Stemtech Corporation’s total current assets stands at $763979.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $23170.00 compared to accounts payable of $0 and inventory worth $225719.00.
In 2025, Stemtech Corporation's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Stemtech Corporation paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $0.04
- 52-Week High
- $1.7
- 52-Week Low
- $0.0311
- Analyst Target Price
- $
Stemtech Corporation stock is currently trading at $0.04 per share. It touched a 52-week high of $1.7 and a 52-week low of $1.7. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.05 and 200-day moving average was $0.09 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7564% of the company’s stock are held by insiders while 894.5% are held by institutions.
Frequently Asked Questions About Stemtech Corporation
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. Its products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. The company offers its dietary supplements products under the RCM System, stemrelease3, Stemflo MigraStem, OraStem, and D-Fuze brand names; and skincare products under the Cellect One brand name. It serves through independent distributors. Stemtech Corporation is headquartered in Miramar, Florida.